Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain. (5th February 2018)

• Record Type: Journal Article
• Authors: Matsuzaki, Yasunori; Konno, Ayumu; Mochizuki, Ryuta; Shinohara, Yoichiro; Nitta, Keisuke; Okada, Yukihiro; Hirai, Hirokazu
• Is Part Of: Neuroscience letters. Volume 665(2018)
• Page Start: 182
• Page End: 188
• Publication Date: 2018-02-05
• Subjects: AAV adeno-associated virus -- BBB blood brain barrier -- ChAT choline acetyltransferase -- CNS central nervous system; Marmoset -- Adeno-associated virus -- AAV9 -- AAV-PHP.B -- Blood brain barrier -- Transcytosis; Neurology -- Periodicals; Neurology -- Periodicals; Research -- Periodicals; Neurologie -- Périodiques; Neuroanatomie -- Périodiques; Neuropharmacologie -- Périodiques; Neurophysiologie -- Périodiques; Neurology; Periodicals; Electronic journals; 617.48
• DOI: 10.1016/j.neulet.2017.11.049
• Languages: English
• ISSNs: 0304-3940

Abstract

Highlights: Adeno-associated virus AAV-PHP.B is a capsid variant of AAV9 vector. AAV-PHP.B has great potential to cross the blood-brain barrier (BBB) in mice. Intravenous injection of AAV9 transduced only ∼3% of the CNS cells in marmosets. Systemic injection of AAV-PHP.B did not alter CNS transduction in marmosets. Results implicate species-specific capsid sequence efficiently crossing the BBB. Abstract: Intravenous administration of adeno-associated virus (AAV)-PHP.B, a capsid variant of AAV9 containing seven amino acid insertions, results in a greater permeability of the blood brain barrier (BBB) than standard AAV9 in mice, leading to highly efficient and global transduction of the central nervous system (CNS). The present study aimed to examine whether the enhanced BBB penetrance of AAV-PHP.B observed in mice also occurs in non-human primates. Thus, a young adult (age, 1.6 years) and an old adult (age, 7.2 years) marmoset received an intravenous injection of AAV-PHP.B expressing enhanced green fluorescent protein (EGFP) under the control of the constitutive CBh promoter (a hybrid of cytomegalovirus early enhancer and chicken β-actin promoter). Age-matched control marmosets were treated with standard AAV9-capsid vectors. The animals were sacrificed 6 weeks after the viral injection. Based on the results, only limited transduction of neurons (0–2%) and astrocytes (0.1–2.5%) was observed in both AAV-PHP.B- and AAV9-treated marmosets. One noticeable difference between AAV-PHP.B and AAV9 was the marked transduction of the peripheral dorsal root ganglia neurons. Indeed, the soma and axons in the projection from the spinal cord to the nucleus cuneatus in the medulla oblongata were strongly labeled with EGFP by AAV-PHP.B. Thus, except for the peripheral dorsal root ganglia neurons, the AAV-PHP.B transduction efficiency in the CNS of marmosets was comparable to that of AAV9 vectors.